We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Henry Schein (HSIC) Tops Q4 Earnings and Revenues Estimates
Read MoreHide Full Article
Headquartered in Melville, NY, Henry Schein Inc. (HSIC - Free Report) is a global leading provider of healthcare products and services. The company serves office-based dental, medical and animal health practitioners, dental laboratories, government as well as institutional health care clinics and other alternate-care sites. Presently, Henry Schein serves more than 1 million customers and has operations in 28 countries. The company entered the prestigious Standard & Poor's (S&P) 500 Index in Mar, 2015.
Currently, Henry Schein has a Zacks Rank #4 (Sell) but that could change following its impressive fourth quarter 2016 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate remained steady at $1.84 per share over the last 60 days. Henry Schein’s adjusted earnings per share of $1.88 beat this estimate by 2.2%.
Full-year 2016 adjusted earnings came in at $6.61 per share which also surpassed the Zacks Consensus Estimate of $6.58 by 0.5%.
Revenues: Henry Schein posted revenues of $3.12 billion, ahead of the Zacks Consensus Estimate for revenues of $3.09 billion.
Full-year 2016 revenues came in at $11.57 billion which also exceeded the Zacks Consensus Estimate figure of $11.53 billion.
Key Stats: Revenues in the fourth quarter derived from Henry Schein’s Dental segment grew 7.7% year over year to $1.54 billion, while Animal Health segment recorded sales of $837.8 million, up 10.8% compared with the prior-year quarter. Revenues from Medical segment increased 10.6% year over year to $621.0 million, while sales from Technology and Value-added services segment grew 19.6% to $112.2 million.
Major Factors: Henry Schein ended fourth quarter of 2016 on an impressive note, with all four of its operating segments delivering strong year over year growth. Management was particularly upbeat with strategic acquisitions that the company made in its technology and Value–Added Services segment. Henry Schein affirmed adjusted EPS guidance for 2017.
Stock Price: Following the earnings release, share prices did not show any significant movement in the pre-market trading session.
Check back later for our full write up on this Henry Schein earnings report later!
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? Last year's market-beating Top 10 portfolio produced 5 double-digit winners. For example, oil and natural gas giant Pioneer Natural Resources and First Republic Bank racked up stellar gains of +44.9% and +44.3% respectively. Now a brand-new list for 2017 has been hand-picked from 4,400 companies covered by the Zacks Rank. See the 2017 Top 10 right now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Henry Schein (HSIC) Tops Q4 Earnings and Revenues Estimates
Headquartered in Melville, NY, Henry Schein Inc. (HSIC - Free Report) is a global leading provider of healthcare products and services. The company serves office-based dental, medical and animal health practitioners, dental laboratories, government as well as institutional health care clinics and other alternate-care sites. Presently, Henry Schein serves more than 1 million customers and has operations in 28 countries. The company entered the prestigious Standard & Poor's (S&P) 500 Index in Mar, 2015.
Currently, Henry Schein has a Zacks Rank #4 (Sell) but that could change following its impressive fourth quarter 2016 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate remained steady at $1.84 per share over the last 60 days. Henry Schein’s adjusted earnings per share of $1.88 beat this estimate by 2.2%.
Full-year 2016 adjusted earnings came in at $6.61 per share which also surpassed the Zacks Consensus Estimate of $6.58 by 0.5%.
Henry Schein, Inc. Price and EPS Surprise
Henry Schein, Inc. Price and EPS Surprise | Henry Schein, Inc. Quote
Revenues: Henry Schein posted revenues of $3.12 billion, ahead of the Zacks Consensus Estimate for revenues of $3.09 billion.
Full-year 2016 revenues came in at $11.57 billion which also exceeded the Zacks Consensus Estimate figure of $11.53 billion.
Key Stats: Revenues in the fourth quarter derived from Henry Schein’s Dental segment grew 7.7% year over year to $1.54 billion, while Animal Health segment recorded sales of $837.8 million, up 10.8% compared with the prior-year quarter. Revenues from Medical segment increased 10.6% year over year to $621.0 million, while sales from Technology and Value-added services segment grew 19.6% to $112.2 million.
Major Factors: Henry Schein ended fourth quarter of 2016 on an impressive note, with all four of its operating segments delivering strong year over year growth. Management was particularly upbeat with strategic acquisitions that the company made in its technology and Value–Added Services segment. Henry Schein affirmed adjusted EPS guidance for 2017.
Stock Price: Following the earnings release, share prices did not show any significant movement in the pre-market trading session.
Check back later for our full write up on this Henry Schein earnings report later!
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? Last year's market-beating Top 10 portfolio produced 5 double-digit winners. For example, oil and natural gas giant Pioneer Natural Resources and First Republic Bank racked up stellar gains of +44.9% and +44.3% respectively. Now a brand-new list for 2017 has been hand-picked from 4,400 companies covered by the Zacks Rank. See the 2017 Top 10 right now>>